Feature: BioCurex - Is the Best Yet to Come?

From our initial Trading Alert in October 2003 at 17 cents, through the price spike to $3.90 a few months later, the SEC halt, the semi-exclusive deal with Abbot Labs, as well as a parade of substantive and exciting clinical results, all have contributed to a plethora of price movements and some great trading opportunities. 

If none of the challenges had occurred and the shares had organically risen to their current 85-cent level over the last two years that would be no disappointment in light of an impressive 400 percent return; as well as little doubt by investors regarding the company’s potential. As I said, never dull.

Long-term, risk-oriented investors should continue to accumulate BOCX shares. 

With the recent sell-off, the chart looks very interesting. The blue 3x3 line, which was held during the sell-off, is now being violated with some conviction. Technically, that can evidence a strong reversal signal to the pullback and we believe a purchase here with a stop at 80 cents has excellent risk/reward characteristics. With the recent volatility in the stock —a good thing-- accumulation at these levels looks positive for traders and long-term investors, in our opinion.

In September, CEO Dr. Ricardo Moro and two of BOCX’s impressive science advisory board—Dr’s Gold and Uriel-- were invited to the ISOBM Conference in Rhodes and presented papers regarding Cancer markers (including RECAF ™) and discussions of BioCurex’s ongoing research and technologies. By all accounts, the presentations were well received and could well lead to more research relationships and, as a result of the exposure at this prestigious conference, more licensing deals as well. As Dr. Moro stated in the recent press release:

“We were also approached by three new large diagnostic companies who have been following our developments and are interested in different aspects of our technology”.

We have always felt that new deals to complement the Abbott deal would appear and the exposure and interest shown at the ISOBM likely went a long way to advancing that process. The entire Press Release regarding the conference is here: http://biz.yahoo.com/pz/051004/87250.html. 

Rome Wasn’t Built in a Day.

Neither was BioCurex. When you are dealing with cutting edge biotechnology and R&D, be it the RECAF™ blood test, or the very exciting potential of BOCX’s work in imaging and therapy, the timelines tend to be long. We are very excited about the preliminary discussions regarding this phase of BOCX’s work and is one of the points discussed in the Letter to Shareholders posted today on BOCX’s website. The topics covered by Dr. Moro in this detailed update include:

• The current state of our technology.
• The size and scope of our targeted markets.
• A discussion of our financing procedures.
• Pink sheets and alternative listing.
• Investor Relations
• Investment Banking
• Our Conclusions

Investors would apparently like the process to move along faster. Get over it. The sector in which BOCX finds itself is thick with products and potential. The challenge is getting to the people and companies that can help advance the technologies through research partnerships including blind studies as well as those partners, such as Abbott, who can move the products forward to commercialization for the benefit of patients and ultimately shareholders. How many other young, smallcap companies can you name that have inked such an impressive deal with a massive pharma so early in their life? 

Not many, if any.

As well, most biotechs in the cancer marker business set up a company to find a marker. BioCurex found the marker and then set up the company. That’s a big difference and a huge advantage over others who might claim eventual success.

Over the last 40 years, there have been roughly half a dozen cancer markers found. The chance of that number rising significantly is fairly slim. We have seen the success of markers such as PSA and CEA. We believe that RECAF™ represents the next generation for both cancer markers and developed tests and technology to make a substantial diagnostic and therapeutic difference to patients and the medical community.

Looking for BOCX or indeed any biotech to rocket tomorrow is like waiting for an earthquake on the west coast. One knows it will come, but obsessing about it is likely more traumatic than the event itself. 

BOCX is the province of those investors with patience who can understand both the risks and potential of a company that appears to have the ability to revolutionize the way cancer is diagnosed and treated.

And, as the company has stated, that will be good for patients and shareholders; in that order.
 
 

We Value Your Feedback

Got comments, questions or suggestions? Send 'em on over: Editor@smallcapdigest.net If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402  San Diego, CA 92130

Subscribe

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition.

Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.smallcapdigest.net/compensation_disclosure.html for our full compensation disclosure and http://www.smallcapdigest.net/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Under SEC Rule 144, 570,000 shares of the 1 million newly issued restricted shares are now eligible for sale into the public market. TGR Group has submitted the approriate filings to sell the shares.  In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares. Additionally, some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee of $3,000 per month to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.